The future looks to be very bright for NXS and the people that may be saved from the perils of antibiotic resistant bacteria (IMHO) through the use of NXS' products. The appendicies to the above presentation outline a significant addressable market in the US alone (DYOR):
Combine this with the continuing decline of daily COVID19 case numbers, and the rollout of COVID vaccines in the US, I can see a scenario developing where the outlook for NXS is one of continuing improvement in the second half of this calendar year. Again IMHO DYOR
Ann: Investor Presentation, page-2
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.015(6.67%) |
Mkt cap ! $70.00M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 24.5¢ | 22.5¢ | $15.37K | 65.99K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 36776 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 3501 | 2 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NXS (ASX) Chart |